7Homograft Ossicles and Tympano-Ossicular Allografts

FWhat a homograft ossicle is

Reconstruction materials for the ossicular chain fall into three families. Autograftsare the patient’s own tissue — a sculpted remnant incus, cortical bone or cartilage. Alloplasts are manufactured prostheses of titanium, hydroxyapatite or porous polyethylene. Between them sits a third, now largely historical, option: the homograft, also called an allograft — tissue taken from a different human, a cadaveric donor, preserved in a tissue bank and later implanted into a recipient. (Tissue from an animal donor would be a xenograft; that is a separate category.)

In otology the homograft could be a single ossicle — most often the incus or malleus— sculpted as a columella or interposition strut. More ambitiously, it could be a whole tympano-ossicular allograft: an intact cadaveric block of tympanic membrane with its malleus and incus attached, transplanted as a unit to rebuild a middle ear gutted by chronic disease. The appeal was obvious. A homograft ossicle has the exact anatomy of the structure it replaces, a mechanical impedance close to native bone, and — for the tympano-ossicular block — it could reconstruct the drum and chain together in one near-physiological step. Crucially, it was available when the patient’s own ossicles had been destroyed by cholesteatoma and no autograft could be harvested.

FThe rise: Marquet and the ossicle banks

The technique is inseparable from one name. In 1966 Jean Marquet, working in Antwerp, pioneered tympano-ossicular allograft tympanoplasty, and over the following decades reported a large clinical experience with it [1977]. His insight was that a single cadaveric tympano-ossicular system could restore both the drum and the conductive mechanism with near-normal anatomy — particularly valuable in ears so badly damaged by chronic otitis media, with or without cholesteatoma, that little usable native tissue remained.

Through the 1970s and early 1980s the approach spread, and dedicated ossicle banks grew up to supply it. Donor ossicles and whole tympano-ossicular blocks were procured at post-mortem, preserved by freeze-drying, irradiation or chemical fixation, and stored for later use. For a time the homograft was the biological material of choice whenever an autograft was unavailable or unsuitable, prized for three things: anatomical congruency (it already had the right shape), biological compatibility (acellular, preserved bony allograft is largely inert and does not provoke hyperacute rejection), and favourable acoustics (its impedance resembled the native ossicle it replaced). It was especially attractive in revision surgery and in total ossicular loss, where the surgeon simply had no native ossicle left to sculpt.

THandling, preservation and the sterilisation dilemma

A homograft is only as good as its preparation, and here lies the central technical tension. Cadaveric tissue must be sterilised to reduce the risk of transmitting infection, yet every method that makes the tissue safer tends to make it worse mechanically. The historic preservation agents — formaldehyde, cialit (a thiomersal-type fixative), and gamma irradiation— reduce viral load but do not reliably inactivate the most feared agent of all, the prion. The more aggressive prion-directed methods, such as 1N sodium hydroxide and autoclaving, are far better at decontamination but significantly degrade the ossicle.

This is not a hand-waving claim. In a controlled biomechanical study, ninety normal ossicles treated with cialit, NaOH or autoclaving each showed a significant fall in ultimate force and stiffness compared with untreated controls; irradiation, meanwhile, embrittles the collagen matrix and predisposes the graft to fragmentation [1999]. The result is a genuine dilemma with no fully satisfying answer: a fresh, untreated ossicle is mechanically ideal but maximally dangerous, while a thoroughly decontaminated one is safe but brittle and prone to resorption and fragmentation after implantation. The widget below lets you feel the trade-off across methods.

Beyond the bench, there are two further handling problems that limited homografts in practice. The first is resorption: homograft ossicles are reabsorbed more readily than autografts on long-term follow-up, causing delayed hearing deterioration. The second is a tendency to ankylose— to fuse to adjacent bony structures such as the facial canal, the bony annulus or the promontory — which tethers the reconstructed chain and limits the very mobility the operation was meant to restore. Both are reasons the early acoustic promise did not always translate into durable hearing.

THearing results: not the weak link

It is tempting to assume homografts were abandoned because they sounded bad. They were not. In properly banked, well-selected cases the hearing results were genuinely competitive. A series of sixty remodelled malleus allograft malleus-to-footplate assemblies recorded a median gain rising from 18 dB at two months to 25 dB at one year, with an air–bone gap closed to within 20 dB in 81% of cases and no extrusions across the follow-up [2002]. The whole tympano-ossicular block performed less well — closure within 20 dB in roughly 44%in comparison cohorts — reflecting the greater complexity of transplanting the drum and chain together, but even that is in the range of the early alloplasts of the day.

The take-home is important for understanding the whole story: homograft ossicles were abandoned despite, not because of, their hearing results.When the chain was well coupled and the ear was favourable, an allograft ossicle could match an autograft incus interposition or a titanium PORP. The reasons for their decline lie elsewhere — in safety and in regulation, not in the audiogram.

CThe decline: HIV, prions and regulation

Two epidemics turned cadaveric tissue from an asset into a liability. The first was HIV. From the late 1980s, the possibility of transmitting the virus through banked human tissue forced a reappraisal of every homograft. A widely cited analysis observed that, although ethanol and formaldehyde inactivate HIV in vitro, complete permeation of dense ossicular bone by preservative had never been demonstrated, and recommended donor HIV screening whenever such grafts were used [1988]. That same paper made the more disquieting point that no routine otologic preservation method could be relied upon to inactivate the agent of Creutzfeldt–Jakob disease (CJD).

The prion was the second and decisive blow. CJD is caused by a misfolded protein that is extraordinarily resistantto the sterilisation processes that destroy bacteria and viruses — it survives standard autoclaving, formaldehyde and irradiation [1999]. With the emergence of variant CJD in the 1990s, the use of cadaveric tissue near the neural axis became medico-legally and politically untenable, and national ossicle banks closed across many countries.

It is worth being precise about the actual evidence, because the fear outran it. A careful review found no documented case of HIV transmission, and no reported case of transmissible spongiform encephalopathy, attributable to homograft ossicles used alone; the only two otological CJD cases on record involved cadaveric dura mater and pericardium used for tympanic membrane grafting, not ossicles [2008]. The authors argued that the risk had probably been overstated for ossicles specifically, and urged continued vigilance, donor screening and sterilisation rather than outright abandonment. Nonetheless, an unquantifiableprion risk — one with a long, silent incubation in which absence of documented harm is not proof of safety — combined with the cost and bureaucracy of compliant tissue banking, was enough to settle the matter for most surgeons.

CWhere homografts stand today

Contemporary ossiculoplasty has largely moved on. The defaults are now the patient’s own autograft tissue — which carries zerotransmission risk and remains an excellent, biocompatible, low-extrusion reconstruction — and off-the-shelf alloplasts of titanium and hydroxyapatite, which offer predictable geometry, sterility and shorter operating times. Against these, a homograft offers no acoustic advantage worth its safety and logistic cost, which is why routine ossicle banking has all but disappeared in regions with ready access to alloplasts [1988, 2008].

Homografts have not vanished entirely. Industrially processed allograft ossicles — for example solvent-dehydrated, gamma-irradiated (“Tutoplast”) malleus — have been used in small modern series with good air–bone gap closure, offering a sterile, regulated, off-the-shelf biological strut in selected reconstructions [2014]. And in centres where alloplasts are unavailable for cost or regulatory reasons, properly banked homografts remain a legitimate choice. There is even a theoretical future in which improved preservation and validated prion inactivation could revive them — but for now they are a niche, not the norm.

The clinical bottom line is therefore a layered one. Do notreach for old, unscreened, non-consented banked tissue to solve a stock problem — that is unsafe and legally indefensible. Dounderstand that the homograft’s decline is a story about disease transmission and regulation, not about hearing. And dorecognise that the autograft — the patient’s own incus, cortical bone or cartilage — captures most of the biological appeal of a homograft with none of its hazard, which is precisely why it, rather than the cadaveric ossicle, has endured [1977].